Objectives To determine the association of nailfold videocapillaroscopy(NVC)findings and telangiectasia score with DU history and severity of peripheral vascular involvement(PVI) in Systemic Sclerosis(SSc). Methods Fifty-nine SSc patients fulfilling Leroy and Medsger criteria were evaluated including Telangiectasia Score(TS)(Shah AA et al. J Rheumatol 2010), Modifiye Rodnan Skin Score(MRSS), Valentine Activity Scale(VAS) and Medsger Severity Scale(SS). Qualitative(early, active and late patterns) and semiquantitative assessments [capillary number(CN), irregularly enlarged capillaries(IEC), giant capillaries(GC), capillary ramifications(CR), microhaemorrhages(H), capillary array disorganisation(CAD) and microangiopathy evolution score(MES)]. was performed by NVC(Sulli et al. Ann Rheum Dis 2008) Results The mean age of patients was 45.6 and 91,5% were females. The mean duration of Raynaud’s(RS), non-Raynaud symptoms(NRS), skin involvement(SI)(year) were 6.1±6.5, 3.1±2.0, 3.0±2.0 respectively. Of the patients 20(34%) were diffuse cutaneous,35(59%) were limited and 4(7%) were sine-scleroderma;13(22%) were anti-centromere(+) and 29(49%) were anti-Scl70(+). DU history (DU+) was present in 27(46%) and telangiectases were present in 34(58%). When we compare DU- and DU + groups, the mean score of CN was 1.4±0.7 vs 2.0±0.5*(p<0.001), IEC was 1.4±0.7 vs 1.8±0.6**(p<0.05), MES was 1.8±1.0 vs 2.5±1.5**(p<0.05); early pattern was in 9 vs 1, active pattern was in 16 vs 14, late pattern was in 7 vs 12 patients. Current PVI grouped as Not Severe(SS;0-1)(n=43) or Severe(SS;2-4)(n=16). The frequency of severe PVI was 22% in females(12/54) and 80% in males(4/5). The mean values of TS, MRSS, VAS, SS were similar between groups. When we compare Not Severe and Severe groups, the mean score of CN was 1.5±0.7 vs 2.1±0.4*(p<0.001), MES was 1.8±1.1 vs 2.8±1.6** (p<0.05); early pattern was in 10 vs 0, active pattern was in 21 vs 9, late pattern was in 12 vs 7 patients. Conclusions DU history and severe PVI in SSc was associated with capillary loss and microangiopathy. ‘Early’ NVC pattern was very rare in patients with DU history and was not found in severe PVI. Severe PVI in males was more frequent than females. Telangiectasia scores were not found to be related to PVI. NVC may be a helpful method in the assessment of SSc patients for PVI prognosis, warranting prospective studies. Disclosure of Interest None Declared

No abstract

Objective Ultrasonography of major salivary glands (SGUS) is a widely used imaging technique to evaluate salivary gland involvement in primary Sjögren’s syndrome (pSS). The aim of this study was to evaluate the relationship between SGUS, salivary flow rate (SFR) as an objective measure of the gland function and oral health-related quality of life (OHRQoL) as a patientreported outcome measure (PROM) in a pSS cohort. Methods Sixty-six patients with pSS were examined by SGUS according to Hocevar and Milic scoring systems. Patients with inhomogeneity/hypoechoic areas with scores ≥2 in parotid and submandibular glands were classified separately as severe glandular involvement. Furthermore, oral health, SFR and oral health impact profile-14 (OHIP-14) for OHRQoL were assessed. Results Both total Hocevar and Milic scores were higher in 21 pSS patients with low unstimulated whole salivary flow rate (U-WSFR) than 45 pSS patients without low U-WSFR (p=0.001 and p<0.0001, respectively). Increased scores of homogeneity, hypoechoic areas and glandular border visibility were observed in patients with low U-WSFR (p<0.05). Among these variables, homogeneity score was found to be an independent risk factor for low UWSFR in pSS according to logistic regression analysis (OR:1.586, p=0.001). Moreover, a higher OHIP-14 score was observed in severe parotid involvement compared to non-severe ones (23.26 ± 21.19 vs 8.32 ±13.82, p=0.004). Conclusion High Milic and Hocevar SGUS scores are associated with reduced SFRs and poor OHRQoL as a PROM. US inhomogeneity of salivary glands is associated with low UWSFR and is a good indicator of severely affected gland function.

A single center survey study of systemic vasculitis and COVID-19 during the first months of pandemic INTRODUCTION: COVID-19 pandemic created concerns among patients receiving immunosuppressive therapy. Frequency of COVID-19 and impact of lockdown on treatment compliance in patients with vasculitis are largely unknown.PATIENTS AND METHOD: Patients with ANCA-associated and large vessel vasculitis that have been followed-up in our clinic were contacted by phone and a questionnaire containing home isolation status, treatment adherence and history of COVID-19 between March 1st and June 30th, 2020 was applied. RESULTS: The survey was applied to 103 patients (F/M: 59/44, mean age: 53.2±12.5). Thirtythree (32%) patients didn't attend at least one appointment; 98(95.1%) noted that they spent 3 months in home isolation. Five patients (4.8%) received immunosuppressives irregularly and 3(2.9%) developed symptoms due to undertreatment. Four (3.9%) patients admitted to hospital with a suspicion of COVID-19, but none of them had positive PCR or suggestive findings by imaging. COVID-19 diagnosed in a patient with granulomatosis with polyangiitis during hospitalization for disease flare and she died despite treatment. DISCUSSION: Frequency of COVID-19 was low in patients with vasculitis in our single center cohort during the first months of pandemic. Although outpatient appointments were postponed in one-third of our patients, high compliance with treatment and isolation rules ensured patients with vasculitis overcome this period with minimal morbidity and mortality.

BackgroundIn patients with seronegative rheumatoid arthritis (RA) there is a difficulty to make the differential diagnosis with the spondyloarthropathies.ObjectivesTo assess the presence of enthesitis in patients with seronegative RA in comparison with the healthy controls (HC), patients with seropositive RA and ankylosing spondylitis(AS).MethodsIn this cross-sectional study, seronegative and seropositive RA patients, who fulfilled the 2010 ACR/EULAR criteria, patients with AS and HC have been assessed by grey scale and power doppler ultrasonography for the presence of enthesopathy at the achilles tendon, plantar fascia, proximal patella, distal patella, quadriceps, tibialis anterior, triceps, common flexor and extensor tendons. Clinical assessment of the patient groups included demographic findings, health assessment questionnaire and DAS28.ResultsIn our study, we recruited age and sex matched 27 seronegative RA, 19 healthy controls, 24 seropositive RA and 23 ankylosing spondylitis patients. We evaluated and analysed both right and left sides of the enthesis regions separately which have been indicated in the methods section. The mean DAS28, mean ESR and mean CRP of the patients with seronegative RA were 3.6±1.28, 32.2±21.2 and 12.37±27.77 respectively (table 1).Median of Madrid sonographic enthesitis index (MASEI) was 5 in patients with seronegative RA. 4 patients have severe scores (MASEI score ≥20). There were significant differences between seronegative RA and healthy controls (MASEI score:3), (p=0.014) but no differences has been observed between seronegative RA with seropositive RA (MASEI score:6) and anklosing spondylitis (MASEI score:7) in MASEI scores.In comparison, hypoechogenicity of quadriceps tendon (16 (29.6%) vs 6 (12.5%), p=0.037), bone erosion at the quadriceps tendon attachment (9 (16.6%) vs 0, p=0.003), calsification at achilles tendon (17 (31.4%) vs 6 (12.5%), p=0.023) have been observed more frequently in patients with seronegative RA than seropositive RA. Significantly higher number of patients with bone erosion at the common extansor tendon (26 (48.1%) vs 3 (6.5%), p=<0.001), calsification at achilles tendon (17 (31.4%) vs 2 (4.3%), p=0.024), erosion at triceps tendon (13 (24%) vs 1 (2.1%), p=0.035) have been detected in patients with ankylosing spondylitis than seronegative RA (table 2).Abstract AB1229 – Table 1Seronegative RAHealthy control groupSeropositive RAAnkylosing spondylitis Age, years51,85±11,4946,2±6,653,12±10,9543,75±4,1Women, n (%)48 (88,9)38 (100)44 (91,7)38 (82,6)RA duration, year9,8±6,75NA 12,29±9,3NARF titre, median10,77±3,21NA323,68±372,72NAAntiCCP titre, median3,99±4,13NA300,16±264,93NADAS28, median3,6±1,28NA3,73±1,45NAESR, median32,2±21,2NA38,73±26,8838,72±9,16CRP, median12,37±27,77NA12,73±18,5710,38±9,3Abstract AB1229 – Table 2Assessing patients with seronegative rheumatoid arthritis about enthesopathy by ultrasound- Pathological findingsConclusionsWe observed that enthesis involvement was not seldom in patients with seronegative RA. Furthermore there were also similar...